Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Abstract: Relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy remains a major challenge in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). One of the main strategies to avoid CD19-negative relapse has been the development of dual CAR T cells...
Saved in:
Main Authors: | Gustavo de Oliveira Canedo, Claire Roddie, Persis J. Amrolia |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Blood Advances |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924007006 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia
by: V. S. Adonyeva, et al.
Published: (2015-03-01) -
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01) -
ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma
by: Saffron E. Summers, et al.
Published: (2023-03-01) -
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
by: Rossana Di Staso, et al.
Published: (2024-11-01)